3 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow Stayble Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| STA363 in the Treatment of Lumbar Disc Herniation Lactic Acid, Placebo - Lumbar Disc Herniation | Phase 1 | Completed | Stayble Therapeutics | 25 | 2023-07-25 | 2025-12-10 |
| Study Investigating STA363 Compared to Placebo in Patients With Chronic Discogenic Low Back Pain STA363 containing 90 mg (60 mg/mL) lactic acid, STA363 containing 180 mg (120 mg/mL) lactic acid, Placebo - Discogenic Pain | Phase 2 | Completed | Stayble Therapeutics | 110 | 2020-07-31 | 2025-12-10 |
| A Single Ascending Dose Study of Safety and Tolerability of STA363 Compared to Placebo in 15 Patients With Chronic Discogenic Low Back Pain STA363, Placebo - Low Back Pain | Phase 1 | Completed | Stayble Therapeutics | 15 | 2017-03-27 | 2020-02-18 |
Intervertebral Disc Displacement (1) · Low Back Pain (1) · Radiculopathy (1)
Lactic Acid (2)
Netherlands (1) · Poland (1) · Russia (1) · Spain (1) · Sweden (1)
Jan Willem Kallewaard, MD, PhD (1)
2015 (1), 2019 (1)